Genoa acquires Medication Management Systems
TUKWILA, Wash. — Behavioral health pharmacy and telepsychiatry company Genoa, a QoL Healthcare company, has acquired Medication Management Systems, enabling the introduction of its medication therapy management technology offering, Genoa Medication Management Solutions.
The technology acquired from Medication Management systems allows for improved treatment plans by making recommendations related to pharmaceutical care for patients with multiple conditions.
“The combination of our capabilities provides an end-to-end solution that strengthens and expands our comprehensive pharmacy offerings,” Genoa CEO John Figueroa said. “As a company, we are focused on providing interventions that continue to achieve more than 90% medication adherence rates. This acquisition enables us to do that for more people,” he said.
Medication Management Systems currently provides medication management services to more than 30,000 patients through health plans, and Medicare and Medicaid managed care organizations with more than 4 million members 300 Centers for Medicare and Medicaid Services contracts license its platforms.
“We already do a great job of improving the lives of those living with a mental illness,” Genoa chief commercial officer Mark Peterson said. “Many people with complex health conditions also have underlying mental health issues. This enables us to serve a broader population.”
MMS also is participating in a CMS innovations program to offer enhanced MTM services to Medicare beneficiaries. The company was founded in 2006 when it was spun out of the newly formed University of Minnesota Venture Center.
"We are very excited to become part of Genoa," MMS CEO and chairman David McLean said. "Genoa’s national footprint, deep industry relationships and expertise providing comprehensive pharmacy solutions to high-risk populations, combined with our patient-centered comprehensive medication management service and technology platform, position us for success far into the future."
VUMC to operate 14 Tennessee retail clinics within Walgreens
NASHVILLE, Tenn. — Walgreens and Vanderbilt University Medical Center on Wednesday announced that a subsidiary of VUMC will operate and provide all clinical services at 14 retail health clinics within Walgreens stores across middle Tennessee.
“We are pleased to announce this new collaborative relationship with Walgreens, which reflects the efforts of both our organizations to make high-quality health care services more accessible and coordinated for patients living throughout Middle Tennessee,” stated Wright Pinson, deputy CEO and chief health system officer for VUMC. “Walgreens is a widely recognized industry leader and we look forward to sharing with them our commitment to improve the health of those we serve.”
“This is a great opportunity for Walgreens to work even closer with Vanderbilt Health,” added Pat Carroll, chief medical officer for Walgreens Healthcare Clinics. “Today’s announcement demonstrates our ongoing commitment to collaborate with community health systems, like Vanderbilt Health, to offer convenient access to affordable healthcare services while helping to ensure a true continuum of care for our patients.”
The announcement builds upon the continued relationship between Walgreens and Vanderbilt Health, which has included infusion services provided throughout the middle Tennessee market and Walgreens pharmacy participation in VUMC’s clinically integrated network.
The existing clinics at these locations, currently managed by Walgreens, are planned to transition to VUMC in November, and will be an extension of the Vanderbilt Health System. The clinics will be known as Vanderbilt Health Clinic at Walgreens. Walgreens will continue to manage these clinic locations until the transition.
FDA grants full approval to Amgen’s Blincyto
SILVER SPRING, Md. — Patients with a certain type of acute lymphoblastic leukemia have a new treatment option. The Food and Drug Administration has granted Amgen’s Blincyto (blinatumomab) full approval for the treatment of Philadelphia Chromosome-positive relaped or refractory B-cell precursor ALL.
“We are pleased that the FDA has granted full approval for Blincyto, marking a significant milestone for certain patients with relapsed or refractory ALL,” Amgen EVP research and development Dr. Sean Harper said. “This approval supports the use of Blincyto in a broader spectrum of patients, including those with few options to date, such as Philadelphia chromosome-positive patients, and reinforces the potential of the [bispeciic T cell engager] platform as a novel approach to immuno-oncology.”
The drug had previously been granted breakthrough therapy designation and accelerated approval.
“Relapsed or refractory ALL is often a lethal disease, with a median overall survival of just four months on standard-of-care chemotherapy,” Moffitt Cancer Center oncologist Dr. Bijal Shah said. “As a physician, my goal is to identify treatments that improve response rates in patients with aggressive hematologic malignancies. Blincyto is an option that has been shown to help these high-risk patients fight their disease."